Gembin Injection contains Gemcitabine, a chemotherapy medication used to treat various types of cancer. It is administered intravenously and is available in different strengths, including 200 mg and 1000 mg formulations. Gemcitabine is a nucleoside analog that interferes with DNA synthesis, inhibiting the proliferation of cancer cells.

Mechanism of Action

Gemcitabine is a prodrug that, once inside the cell, is phosphorylated to its active form, gemcitabine triphosphate. This active metabolite:

• Incorporates into DNA: It is mistakenly incorporated into the growing DNA strand during replication.

• Inhibits DNA synthesis: Its incorporation leads to DNA chain termination and inhibition of DNA polymerase, preventing further DNA synthesis.

  Uses

  Gembin Injection is indicated for the treatment of various cancers, including:

  • Pancreatic Cancer: Used as a first-line treatment for advanced or metastatic pancreatic cancer.

  • Non-Small Cell Lung Cancer (NSCLC): Administered alone or in combination with other chemotherapy agents.

  • Breast Cancer: Often used in combination with other chemotherapy drugs for metastatic breast cancer.

  • Ovarian Cancer: Used in combination with other agents for advanced ovarian cancer.

  • Bladder Cancer: Administered in combination with cisplatin for advanced or metastatic urothelial carcinoma.

    Adverse Effects

    Common side effects of Gembin Injection include:

    • Hematologic Toxicity: Low white blood cell count (neutropenia), low platelet count (thrombocytopenia), and anemia.

    • Gastrointestinal Symptoms: Nausea, vomiting, diarrhea, constipation, and abdominal pain.

    • Fatigue and Weakness: Generalized tiredness and weakness.

    • Hair Loss: Temporary hair thinning or loss.

    • Skin Reactions: Rash, redness, and itching.